Claims for Patent: 8,283,362

Summary for Patent: 8,283,362

Title:	Beta-2-adrenoreceptor agonists
Abstract:	Compounds of formula ##STR00001## in free or salt or solvate form, where Ar is a group of formula ##STR00002## Y is carbon or nitrogen and R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.
Inventor(s):	Cuenoud; Bernard (Horsham, GB), Bruce; Ian (Horsham, GB), Fairhurst; Robin A (Horsham, GB), Beattie; David (Horsham, GB)
Assignee:	Novartis AG (Basel, CH)
Application Number:	13/295,426
Patent Claims:	1. An inhalable pharmaceutical composition comprising: (a) (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one in free or salt or solvate form; (b) an anticholinergic or antimuscarinic agent; and (c) a pharmaceutically acceptable carrier in inhalable form. 2. An inhalable pharmaceutical composition according to claim 1, that contains a daily dose of (a). 3. An inhalable pharmaceutical composition according to claim 2, in which the daily dose of (a) is from 1 .mu.g to 5000 .mu.g. 4. An inhalable pharmaceutical composition according to claim 3, which is a dry powder formulation. 5. An inhalable pharmaceutical composition according to claim 1, in which (a) is (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-- 1H-quinolin-2-one maleate. 6. An inhalable pharmaceutical composition according to claim 5, that contains a daily dose of (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one maleate. 7. An inhalable pharmaceutical composition according to claim 6, in which the daily dose of (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one maleate is from 1 .mu.g to 5000 .mu.g. 8. An inhalable pharmaceutical composition according to claim 7, which is a dry powder formulation. 9. An inhalable pharmaceutical composition according to claim 1, in which (b) is an anticholinergic or antimuscarinic agent selected from the group consisting of ipratropium bromide, oxitropium bromide and tiotropium bromide. 10. An inhalable pharmaceutical composition according to claim 9, in which (b) is tiotropium bromide. 11. An inhalable pharmaceutical composition according to claim 1, in which (a) is (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one in free or salt or solvate form and (b) is tiotropium bromide. 12. An inhalable pharmaceutical composition according to claim 11, in which (a) is (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one maleate and (b) is tiotropium bromide. 13. An inhalable pharmaceutical composition according to claim 12, which is a dry powder formulation. 14. An inhalable pharmaceutical composition according to claim 1, which is a dry powder formulation. 15. A method of treating a patient with an obstructive or inflammatory airways disease which comprises administering to the patient in need of such treatment an inhalable pharmaceutical composition according to claim 1. 16. A method of treating a patient according to claim 15, in which the obstructive or inflammatory airways disease is chronic obstructive pulmonary or airways disease. 17. A method of treating a patient with an obstructive or inflammatory airways disease which comprises administering to the patient in need of such treatment an inhalable pharmaceutical composition according to claim 5. 18. A method of treating a patient according to claim 17, in which the obstructive or inflammatory airways disease is chronic obstructive pulmonary or airways disease. 19. A method of treating a patient with an obstructive or inflammatory airways disease which comprises administering to the patient in need of such treatment an inhalable pharmaceutical composition according to claim 9. 20. A method of treating a patient according to claim 19, in which the obstructive or inflammatory airways disease is chronic obstructive pulmonary or airways disease.